Clinical Trial Update: A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. [Phase 3]

View source ↗

Summary

A Phase III randomized trial evaluated whether a longer consolidation treatment with nilotinib affects treatment-free remission in chronic-phase Philadelphia ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia
• Phase Philadelphia Chromosome-positive CML

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | Phase 3 | Status: COMPLETED | Results posted: 2021-07-15